Flare Therapeutics Announces Strategic Collaboration with Roche in Oncology
Deal News | Nov 12, 2024 | Agent Capital LLC
Flare Therapeutics, a biotech firm specializing in targeting transcription factors for therapeutic discoveries, has announced a strategic collaboration with Roche, a global leader in the pharmaceutical industry. The collaboration aims to leverage Flare Therapeutics' proteomic and mass spectrometry platform, alongside its proprietary library of electrophilic compounds, to discover new small molecule drugs targeting previously undruggable transcription factors in oncology. Flare will receive a $70 million upfront payment and could earn over $1.8 billion in milestone payments, in addition to royalties. The partnership signifies a significant step in tackling oncological diseases with high unmet medical needs by developing innovative treatments that current standard-of-care therapies do not address. Flare will lead discovery and preclinical activities, while Roche will handle further clinical development and commercialization. This venture highlights the potential of integrating advanced drug discovery technologies to unlock new therapeutic pathways in oncology.
Sectors
- Biotechnology
- Pharmaceuticals
- Life Sciences
Geography
- United States – Flare Therapeutics is based in Cambridge, Massachusetts, and will lead discovery efforts from this location, situating part of the collaboration geographically in the U.S.
- Switzerland – Roche, headquartered in Switzerland, represents the European geographic base of the collaboration and will lead clinical development and commercialization from this region.
Industry
- Biotechnology – The article discusses Flare Therapeutics, a biotechnology firm, focusing on drug discovery for oncology through targeting transcription factors, which are central to this industry.
- Pharmaceuticals – Roche, a global pharmaceutical company, is partnering with Flare Therapeutics to advance the development and commercialization of new cancer therapies, emphasizing its role in the industry.
- Life Sciences – Both companies are engaged in scientific research aimed at developing therapeutic solutions for complex diseases, highlighting the life sciences sector's focus on innovation and drug development.
Financials
- US$70 million – Upfront payment to Flare Therapeutics as part of the collaboration with Roche.
- US$1.8 billion – Potential milestone payments to Flare Therapeutics based on discovery, development, and commercialization targets.
- Royalties – Additional financial benefits Flare Therapeutics is eligible to receive from the commercialization of potential products.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Flare Therapeutics Inc. | Target company and collaborative partner with Roche, focusing on discovery and preclinical activities. | Company | A clinical-stage biotechnology company focused on drugging transcription factors to discover precision medicines for oncology. |
| Roche | Collaborative partner focusing on further clinical development and commercialization. | Company | A leading global pharmaceutical company known for its expertise in oncology. |
| Agent Capital LLC | Private Equity firm mentioned as backing Flare Therapeutics. | Company | A private equity firm likely involved with investments in the biotechnology sector, associated with Flare Therapeutics. |
| Rob Sims, Ph.D. | Chief Scientific Officer and Co-founder of Flare Therapeutics. | Person | Overseeing scientific development and strategic collaborations at Flare Therapeutics. |
| Boris L. Zatra | Head of Roche Corporate Business Development. | Person | Leading business development initiatives at Roche, including strategic collaborations. |